Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31658| Title: | Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. | Austin Authors: | Ghosh, Nilasha;Couette, Nina;van Binsbergen, Wouter H;Weinmann, Sophia C;Jivanelli, Bridget;Shea, Beverley;Bass, Anne R;Benesova, Karolina;Bingham, Clifton O;Calabrese, Cassandra;Cappelli, Laura C;Chan, Karmela Kim;Choy, Ernest;Daoussis, Dimitrios;Goodman, Susan;Hudson, Marie;Jamal, Shahin;Leipe, Jan;Lopez-Olivo, Maria A;Suarez-Almazor, Maria;van der Laken, Conny J;Meara, Alexa Simon;Liew, David F L ;Kostine, Marie | Affiliation: | Department of Medicine, Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, 535 E 70th St, New York, NY, USA. Department of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, USA. Amsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL Amsterdam, the Netherlands. Department of Rheumatology & Immunology, Duke University, Durham, NC, USA. Hospital for Special Surgery, Kim Barrett Memorial Library, HSS Education Institute, New York, NY, USA. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada. Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany. Division of Rheumatology, Johns Hopkins University, Baltimore MD, USA. Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA. Rheumatology CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom. Department of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece. Jewish General Hospital, Lady Davis Institute for medical research and McGill University, Montreal, Quebec, Canada. Vancouver Coastal Health, University of British Columbia, Vancouver, BC, Canada. Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Germany. The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Clinical Pharmacology and Therapeutics Bordeaux University Hospital, Department of Rheumatology, France. Medicine (University of Melbourne) |
Issue Date: | 2023 | Date: | 2022-10 | Publication information: | Seminars in Arthritis and Rheumatism 2023 | Abstract: | Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31658 | DOI: | 10.1016/j.semarthrit.2022.152110 | ORCID: | Journal: | Seminars in Arthritis and Rheumatism | Start page: | 152110 | PubMed URL: | 36372016 | ISSN: | 1532-866X | Type: | Journal Article | Subjects: | ICI-induced inflammatory arthritis ICI-induced polymyalgia rheumatica Immune checkpoint inhibitor Outcome measures |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.